BNP PARIBAS FINANCIAL MARKETS - CELLULAR BIOMEDICINE GROUP I ownership

CELLULAR BIOMEDICINE GROUP I's ticker is CBMG and the CUSIP is 15117P102. A total of 43 filers reported holding CELLULAR BIOMEDICINE GROUP I in Q1 2020. The put-call ratio across all filers is - and the average weighting 0.0%.

Quarter-by-quarter ownership
BNP PARIBAS FINANCIAL MARKETS ownership history of CELLULAR BIOMEDICINE GROUP I
ValueSharesWeighting
Q4 2020$47,255,000
-15.5%
2,571
-15.7%
0.00%
Q3 2020$55,919,000
+701.6%
3,049
+554.3%
0.00%
Q2 2020$6,976,000
-88.3%
466
-87.6%
0.00%
Q1 2020$59,452,000
+75.3%
3,758
+80.0%
0.00%
Q4 2019$33,909,000
+18.5%
2,088
+8.4%
0.00%
Q3 2019$28,620,000
+8.7%
1,926
+20.9%
0.00%
Q2 2019$26,332,000
-38.0%
1,593
-35.1%
0.00%
Q1 2019$42,489,000
+1606.4%
2,456
+1641.8%
0.00%
Q4 2018$2,490,000
-63.8%
141
-62.8%
0.00%
Q3 2018$6,879,000
-9.1%
379
-2.1%
0.00%
Q2 2018$7,566,000
+6051.2%
387
+5428.6%
0.00%
Q1 2018$123,000
+55.7%
70.0%0.00%
Q4 2017$79,000
+5.3%
70.0%0.00%
Q3 2017$75,000
+23.0%
70.0%0.00%
Q2 2017$61,000
-92.0%
7
-89.2%
0.00%
Q1 2017$767,000
-74.8%
65
-72.0%
0.00%
Q4 2016$3,039,000
-76.8%
232
-74.3%
0.00%
Q3 2016$13,108,000
+62.4%
904
+34.3%
0.00%
Q2 2016$8,069,000
+440.8%
673
+741.2%
0.00%
Q1 2016$1,492,000
-96.0%
80
-95.4%
0.00%
Q4 2015$37,736,000
-10.5%
1,756
-29.5%
0.00%
Q3 2015$42,173,000
+37.3%
2,491
+204.2%
0.00%
Q2 2015$30,721,0008190.00%
Other shareholders
CELLULAR BIOMEDICINE GROUP I shareholders Q1 2020
NameSharesValueWeighting ↓
PLATINUM INVESTMENT MANAGEMENT LTD 672,885$11,123,0000.26%
AWM Investment Company, Inc. 80,165$1,325,0000.25%
Nikko Asset Management Americas, Inc. 532,318$8,799,0000.17%
ARK Investment Management 314,378$5,197,0000.13%
Sumitomo Mitsui Trust Holdings, Inc. 528,418$8,735,0000.01%
BRIDGEWAY CAPITAL MANAGEMENT, LLC 32,100$531,0000.01%
Mizuho Securities Co. Ltd. 300$5,0000.01%
GEODE CAPITAL MANAGEMENT, LLC 148,815$2,459,0000.00%
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM 18,629$308,0000.00%
STATE OF WISCONSIN INVESTMENT BOARD 16,100$237,0000.00%
View complete list of CELLULAR BIOMEDICINE GROUP I shareholders